Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 3, 2015, Pages

  Patel, Sanjay ^a   Sinha, Ian P ^a   Dwan, Kerry ^a   Echevarria, Carlos ^b   Schechter, Michael ^c   Southern, Kevin W ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; ASPARTIC ACID; C REACTIVE PROTEIN; CHLORIDE; CREATININE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLUCOSE; GLYCINE; IVACAFTOR; PHENYLALANINE; PLACEBO; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; QUINOLONE DERIVATIVE;

ABDOMINAL DISTENSION; ABNORMAL RESPIRATORY SOUND; ACNE; ADJUSTMENT DISORDER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ANXIETY; ARTHRALGIA; ARTHRITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BODY HEIGHT; BODY MASS; BODY WEIGHT CHANGE; BODY WEIGHT GAIN; BODY WEIGHT LOSS; BRONCHITIS; CFTR GENE; COMPLETE HEART BLOCK; CONSTIPATION; CONTACT DERMATITIS; CONVERSION DISORDER; COUGHING; CRACKLE; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY NOSE; DYSPNEA; EAR INFECTION; EOSINOPHIL COUNT; EPISTAXIS; ERYTHEMA; FATIGUE; FEVER; FLATULENCE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GENE MUTATION; GENITAL PRURITUS; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEADACHE; HEART MURMUR; HEMATURIA; HEMOPTYSIS; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; IMMUNOGLOBULIN A NEPHROPATHY; INFLUENZA; INJECTION SITE EDEMA; KIDNEY COLIC; LACERATION; LENGTH OF STAY; LEUKOCYTE COUNT; LIMB PAIN; LUNG EMBOLISM; LUNG INFECTION; LYMPH NODE PAIN; LYMPHADENOPATHY; MIGRAINE; MOOD DISORDER; MUSCLE STRAIN; MYALGIA; MYOPATHY; NAUSEA; NECK PAIN; NEPHROLITHIASIS; NEUTROPHIL COUNT; NOSE DISEASE; NOSE EDEMA; NOSE OBSTRUCTION; OROPHARYNX PAIN; OTITIS MEDIA; PAIN; PANCREAS PSEUDOCYST; PANCREATITIS; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PYURIA; QUALITY OF LIFE; RASH; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVIEW; RHINITIS; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SINUS CONGESTION; SINUS HEADACHE; SINUSITIS; SOMNOLENCE; SORE THROAT; SPONTANEOUS ABORTION; SPRAIN; SPUTUM DISCOLORATION; STREPTOCOCCAL PHARYNGITIS; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TENSION HEADACHE; TESTIS TORSION; THORAX PAIN; THRUSH; TONSIL DISEASE; TONSILLAR HYPERTROPHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; UTERINE CERVIX CARCINOMA; VOMITING; VULVOVAGINITIS; WHEEZING; ADULT; AGE; CHILD; DRUG EFFECTS; GENETICS; META ANALYSIS; MOLECULARLY TARGETED THERAPY; MUCOCILIARY CLEARANCE; MUTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGE FACTORS; AMINOPHENOLS; CHILD; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORCED EXPIRATORY VOLUME; HUMANS; MOLECULAR TARGETED THERAPY; MUCOCILIARY CLEARANCE; MUTATION; QUALITY OF LIFE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84939463598     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009841.pub2     Document Type: Review

References (123)

1. Accurso F, Rowe SM, Durie PR, Konstan MW, Dunitz J, Hornick D, et al. Improvement in sweat chloride concentration by the CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation [abstract. Pediatric Pulmonology 2009;44(S32):296, Abstract no: 240. [CFGD Register: BD165c; MEDLINE: 98135729]
2. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. New England Journal of Medicine 2010;363(21):1991-2003. [CFGD Register: BD165i; MEDLINE: 98135729]
3. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Online supplementary appendix to "Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation" [online]. New England Journal of Medicine 2010;363(21):1-33 online. [CFGD Register: BD165j; MEDLINE: 98135729]
4. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Online supplementary material (disclosure forms) to "Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation" [online]. New England Journal of Medicine 2010;363(21):1991-2003 online. [CFGD Register: BD165k; MEDLINE: 98135729]
5. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Online supplementary material (protocol) to "Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation" [online]. New England Journal of Medicine 2010;363(21):1-121 online. [CFGD Register: BD165l; MEDLINE: 98135729]
6. Accurso FJ, Rowe SM, Durie PR, Konstan MW, Dunitz J, Hornick DB, et al. Final results of a 14-and 28-day study of VX-770 in subjects with CF. Journal of Cystic Fibrosis 2009;8 Suppl 2:S25, Abstract no: 97. [CFGD Register: BD165d; MEDLINE: 98135729]
7. Accurso FJ, Rowe SM, Durie PR, Konstan MW, Dunitz J, Hornick DB, et al. Interim results of phase 2a study of VX-770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D. Pediatric Pulmonology 2008;43(S1):295, Abstract no: 267. [CFGD Register: BD165b; MEDLINE: 98135729]
8. Accurso FJ, Van Goor F, Zha J, Stone AJ, Dong Q, Ordonez CL, et al. Online Data Supplement to "Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data". Journal of Cystic Fibrosis 2014;13(2):139-147 online. [CENTRAL: 1000304; CFGD Register: BD165r; CRS: 5500131000000025]
9. Accurso FJ, Van Goor F, Zha J, Stone AJ, Dong Q, Ordonez CL, et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis 2014;13(2):139-47. [CENTRAL: 978403; CFGD Register: BD165q; CRS: 5500050000000097; EMBASE: 2014086288]
10. Antoniu SA. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. New England Journal of Medicine 2010;363(21):1991-2003. Expert Opinion on Investigational Drugs 2011;20(3):423-5. [CFGD Register: BD165m; MEDLINE: 98135729]
11. Boyle M, Clancy JP, Rowe SM, Durie P, Dunitz J, Konstan MW, et al. Effect of VX-770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D-CFTR mutation. Pediatric Pulmonology 2009;44(S32):287, Abstract no: 217. [CFGD Register: BD165f]
12. Clancy JP, Rowe SM, Durie P, Freedman S, Dong Q, Ordonez C, et al. NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator. Pediatric Pulmonology 2009;44(S32):288, Abstract no: 222. [CFGD Register: BD165e; MEDLINE: 98135729]
13. Rowe SM, Clancy JP, Boyle M, van Goor F, Ordonez C, Dong Q, et al. Parallel effects of VX-770 on transepithelial potential difference in vitro and in vivo. Journal of Cystic Fibrosis 2010;9 Suppl 1:S20, Abstract no: 74. [CFGD Register: BD165h; MEDLINE: 98135729]
14. Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PloS One 2013;8(7):e66955. [CFGD Register: BD165o; CRS-ID: 5500125000000048]
15. Rowe SM, van Goor F, Clancy JJP, Durie PR, Konstan MW, Dunitz J, et al. Corresponding effects of VW-770 on NPD in vivo & human bronchial epithelial (HBE) cells in vitro. Pediatric Pulmonology 2010;45 Suppl 33:319, Abstract no: 281. [CFGD Register: BD165g]
16. van Goor F, Hadida S, Negulescu P, Clancy JP, Accurso FJ, Ashlock MA, et al. Relationship of VX-770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX-770. Pediatric Pulmonology 2008;43(S31):314, Abstract no: 319. [CFGD Register: BD165a; MEDLINE: 98135729]
17. Aherns R, Rodriguez S, Yen K, Davies JC. VX-770 in subjects 6 to 11 years with cystic fibrosis and the G551D-CFTR mutation. Pediatric Pulmonology 2011;46(S34):283, Abstract no: 203. [CFGD Register: BD171a; MEDLINE: 98135729]
18. Borowitz D, Ramsey B, Dong Q, Yen K, Elborn JS. Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation. Journal of Cystic Fibrosis 2012;11 Suppl 1:S13, Abstract no: WS6.3. [CFGD Register: BD171c//BD170d; CRS-ID: 5500125000000017]
19. Borowitz D, Ramsey B, Rodriguez S, Yen K, Elborn JS. Nutritional status measures among persons with CF carrying the G551D-CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology 2012;47(S35):298, Abstract no: 214. [CFGD Register: BD171f//BD170i; CRS-ID: 5500125000000031]
20. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine 2013;187(11):1219-25. [CFGD Register: BD171g; CRS-ID: 5500125000000049]
21. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, et al. Online Supplement to "Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation" [online]. American Journal of Respiratory and Critical Care Medicine 2013;187(11):1219-1225 online. [CFGD Register: BD171h; CRS-ID: 5500125000000050]
22. Davies KC, Li H, Yen K, Ahrens R, on behalf of theVX08-770-103SG. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D-CFTR mutation. Journal of Cystic Fibrosis 2012;11 Suppl 1:S13, Abstract no: WS6.5. [CFGD Register: BD171b; CRS-ID: 5500125000000018]
23. Elborn JS, Rodriguez S, Lubarsky B, Gilmartin G, Bell S. Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV >90% of predicted. Pediatric Pulmonology 2013;48 Suppl 36:298, Abstract no: 257. [CENTRAL: 921689; CFGD Register: BD171k // BD188e // BD170m; CRS: 5500125000000401]
24. Flume P, Wainwright CE, Tullis E, Rodriguez S, Davies J, Wagener J. Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis 2013;12 Suppl 1:S63, Abstract no: 58. [CFGD Register: BD171j//BD170j; CRS-ID: 5500100000011668]
25. McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). The Lancet. Respiratory Medicine 2014;2:902-10. [CENTRAL: 1017318; CFGD Register: BD171l // BD170n; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995]
26. Plant BJ, Konstan M, Aherns R, Rodriguez S, Munck A, Elborn JS, et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis 2013;12 Suppl 1:S62, Abstract no: 53. [CFGD Register: BD171i//BD170k; CRS-ID: 5500100000011667]
27. Quittner A, Ramsey B, Rodriguez S, Yen K, Elborn JS. Patient-reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation. Pediatric Pulmonology 2012;47 Suppl 35:297, Abstract no: 212. [CFGD Register: BD171e//BD170g; CRS-ID: 5500125000000030]
28. Quittner AL, Ramsey B, Dong Q, Yen K, Elborn JS. Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation. Journal of Cystic Fibrosis 2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD171d//BD170e; CRS-ID: 5500125000000021]
29. Flume PA, Borowitz D, Liou T, Li H, Yen K, Ordonez C, et al. VX-770 in subjects with CF and homozygous for the F508del-CFTR mutation. Pediatric Pulmonology 2011;46 Suppl 34:284, Abstract no: 206. [CFGD Register: BD168b; MEDLINE: 98135729]
30. Flume PA, Borowitz DS, Liou TG, Li H, Yen K, Ordonez CL, et al. VX-770 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Journal of Cystic Fibrosis 2011;10 Suppl 1:S16, Abstract no: 61. [CFGD Register: BD168a; MEDLINE: 98135729]
31. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordonez CL, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012;142(3):718-24. [CFGD Register: BD168c; CRS-ID: 5500125000000051]
32. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordonez CL, et al. Online Supplement to "Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation" [online]. Chest 2012;142(3):718-724 online. [CRS-ID: 5500125000000052;: BD168d]
33. Borowitz D, Ramsey B, Dong Q, Yen K, Elborn JS. Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation. Journal of Cystic Fibrosis 2012;11 Suppl 1:S13, Abstract no: WS6.3. [CFGD Register: BD170d//BD171c; CRS-ID: 5500125000000017]
34. Borowitz D, Ramsey B, Rodriguez S, Yen K, Elborn JS. Nutritional status measures among persons with CF carrying the G551D-CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials. Pediatric Pulmonology 2012;47 Suppl 35:298, Abstract no: 214. [CFGD Register: BD170i//BD171f; CRS-ID: 5500125000000031]
35. Elborn JS, Rodriguez S, Lubarsky B, Gilmartin G, Bell S. Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV >90% of predicted. Pediatric Pulmonology 2013;48 Suppl 36:298, Abstract no: 257. [CENTRAL: 921689; CFGD Register: BD170m // BD171k // BD188e ; CRS: 5500125000000401]
36. Flume P, Wainwright CE, Tullis E, Rodriguez S, Davies J, Wagener J. Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis 2013;12 Suppl 1:S63, Abstract no: 58. [CFGD Register: BD170j//BD171j; CRS-ID: 5500100000011668]
37. Griese M, Ramsey B, Rodriguez S, Yen K, Elborn JS, on behalf of the VX08-770-102 Study Group. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation. Journal of Cystic Fibrosis 2012;11 Suppl 1:S67, Abstract no: 44. [CFGD Register: BD170f; CRS-ID: 5500125000000022]
38. McKone E, Li H, Yen K, Davies JC, on behalf of the VX08-770-105 study group. Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation. Journal of Cystic Fibrosis 2012;11 Suppl 1:S13, Abstract no: WS6.4. [CFGD Register: BD170h; CRS-ID: 5500125000000047]
39. McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). The Lancet. Respiratory Medicine 2014;2:902-10. [CENTRAL: 1017318; CFGD Register: BD170n // BD171l; CRS: 5500131000000246; JID:: 101605555; PUBMED: 25311995]
40. Plant BJ, Konstan M, Aherns R, Rodriguez S, Munck A, Elborn JS, et al. Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis 2013;12 Suppl 1:S62, Abstract no: 53. [CFGD Register: BD170k//BD171i; CRS-ID: 5500100000011667]
41. Quittner A, Ramsey B, Rodriguez S, Yen K, Elborn JS. Patient-reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation. Pediatric Pulmonology 2012;47 Suppl 35:297, Abstract no: 212. [CFGD Register: BD170g//BD171e; CRS-ID: 5500125000000030]
42. Quittner AL, Ramsey B, Dong Q, Yen K, Elborn JS. Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation. Journal of Cystic Fibrosis 2012;11 Suppl 1:S67, Abstract no: 43. [CFGD Register: BD170e//BD171d; CRS-ID: 5500125000000021]
43. Ramsey B, Dong Q, Yen K, Elborn J. Efficacy and safety of VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation. Pediatric Pulmonology 2011;46(S34):286, Abstract no: 211. [CFGD Register: BD170a; MEDLINE: 98135729]
44. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine 2011;365(18):1663-72. [CFGD Register: BD170b; CRS-ID: 5500125000000045]
45. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. Online Supplementary Appendix to "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation" [online]. New England Journal of Medicine 2011;365(18):1663-1672 online. [CFGD Register: BD170c; CRS-ID: 5500125000000046]
46. Seliger VI, Accurso FJ, Konstan MW, Dong Q, Lubarsky B, Mueller P. Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D-CFTR mutation. Pediatric Pulmonology 2013;48 Suppl 36:298, Abstract no: 259. [CENTRAL: 921687; CRS: 5500125000000399;: BD170l]
47. Accurso FJ, Ratjen F, Altes T, Lubarsky B, Dong Q, Kang L, et al. Effect of withdrawal of ivacaftor therapy on CFTR channel activity and lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis 2013;12 Suppl 1:S62, Abstract no: 56. [CFGD Register: BD189//BD188c; CRS-ID: 5500125000000055]
48. Altes T, Johnson M, Higgins M, Fidler M, Botfield M, Mugler III JP, et al. The effect of ivacaftor treatment on lung ventilation defects, as measured by hyperpolarized helium-3 MRI, on patients with cystic fibrosis and a G551D-CFTR mutation. Journal of Cystic Fibrosis 2014;13 Suppl 2:S6, Abstract no: WS3.2. [CENTRAL: 1000056; CFGD Register: BD172d; CRS: 5500131000000009]
49. Altes T, Johnson MA, Miller GW, Mugler JP, Flors L, Mata J, et al. Hyperpolarized Gas MRI of ivacaftor therapy in subjects with cystic fibrosis who have the G551D-CFTR mutation. Journal of Cystic Fibrosis 2012;11 Suppl 1:S67, Abstract no: 46. [CFGD Register: BD172b; CRS-ID: 5500125000000023]
50. Altes T, Johnson MA, Miller GW, Mugler JP, Flors L, Mata J, et al. Hyperpolarized gas MRI of ivacaftor therapy in persons with cystic fibrosis and the G551D-CFTR mutation. Pediatric Pulmonology 2012;47 Suppl 35:291, Abstract no: 196. [CFGD Register: BD172c; CRS-ID: 5500125000000028]
51. Altes T, Johnson MA, Miller GW, Mugler JP, Flors L, Mata J, et al. Hyperpolarized helium-3 magnetic resonance imaging of CFTR potentiator therapy in subjects with cystic fibrosis and the G551D mutation. Pediatric Pulmonology 2011;46(S34):284, Abstract no: 205. [CFGD Register: BD172a; MEDLINE: 98135729]
52. Boyle M, Bell SC, Konstan M, McColley S, Flume P, Kang L, et al. Lumacaftor, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in CF patients with the F508del-CFTR mutation: phase 2 interim analysis. Journal of Cystic Fibrosis 2013;12 Suppl 1:S14, Abstract no: WS7.4. [CENTRAL: 921640; CFGD Register: BD169c; CRS: 5500100000011652]
53. Boyle MP, Bell S, Konstan M, McColley SA, Kang L, Patel N, et al. The investigational CFTR corrector, VX-809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F509-8DEL homozygous patients: phase II study results. Pediatric Pulmonology 2012;47 Suppl 35:315, Abstract no: 260. [CENTRAL: 921644; CFGD Register: BD169b; CRS: 5500125000000037]
54. Boyle MP, Bell S, Konstan MW, McColley SA, Wisseh S, Spencer-Green G. VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508DEL-CFTR Mutation. Pediatric Pulmonology 2011;46 Suppl 34:287, Abstract no: 212. [CFGD Register: BD169a]
55. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial. The Lancet. Respiratory Medicine 2014;2(7):527-38. [CENTRAL: 994993; CFGD Register: BD169d; CRS: 5500050000000081; EMBASE: 2014458184]
56. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al. Supplementary Appendix to "A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial." [online]. The Lancet. Respiratory Medicine 2014;2(7):527-38 online. [CENTRAL: 997711; CFGD Register: BD169e; CRS: 5500125000000703]
57. Chadwick S, Browning JE, Stern M, Cheng SH, Gruenert DC, Geddes DM, et al. Nasal application of glycerol in DF508 cystic fibrosis patients. Pediatric Pulmonology 1998;26 Suppl 17:278. [CFGD Register: BD147]
58. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67(1):12-8. [CFGD Register: BD166c; MEDLINE: 98135729]
59. Clancy JP, Rowe SM, Accurso FJ, Ballmann M, Boyle MP, DeBoeck C, et al. A phase II, randomized, placebo-controlled, clinical trial of four doses of VX-809 in CF patients homozygous for the F508del CFTR mutation. Pediatric Pulmonology 2010;45 Suppl 33:298, Abstract no: 224. [CFGD Register: BD166b; MEDLINE: 98135729]
60. Clancy JP, Rowe SM, Liu B, Hathorne H, Dong Q, Wisseh S, et al. Variability of nasal potential difference measurements in clinical testing of CFTR modulators. Pediatric Pulmonology 2011;46 Suppl 34:283, Abstract no: 202. [CFGD Register: BD165n, BD166d; MEDLINE: 98135729]
61. Clancy JP, Spencer-Green G, for the VX-809-101 Study Group. Clinical evaluation of VX-809, a novel investigational oral F508del-CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Journal of Cystic Fibrosis 2010;9 Suppl 1:S20, Abstract no: 73. [CFGD Register: BD166a; MEDLINE: 98135729]
62. Accurso FJ, Ratjen F, Altes T, Lubarsky B, Dong Q, Kang L, et al. Effect of withdrawal of ivacaftor therapy on CFTR channel activity and lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis 2013;12 Suppl 1:S62, Abstract no: 56. [CFGD Register: BD189//BD190b//BD188c; CRS-ID: 5500125000000055]
63. Davies JC, Sheridan H, Lee P, Song T, Stone A, Ratjen F. Lung clearance index to evaluate the effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease. Pediatric Pulmonology 2012;47 Suppl 35:311, Abstract no: 249. [CFGD Register: BD188b; CRS-ID: 5500125000000034]
64. Davies JC, Sheridan H, Lee PS, Song T, Stone A, Ratjen F, et al. Effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease: a comparison of lung clearance index (LCI) vs. spirometry. Journal of Cystic Fibrosis 2012;11 Suppl 1:S15, Abstract no: WS7.6. [CFGD Register: BD188a; CRS-ID: 5500125000000053]
65. Elborn JS, Rodriguez S, Lubarsky B, Gilmartin G, Bell S. Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV >90% of predicted. Pediatric Pulmonology 2013;48 Suppl 36:298, Abstract no: 257. [CENTRAL: 921689; CFGD Register: BD188e // BD170m // BD171k; CRS: 5500125000000401]
66. Ratjen F, Sheridan H, Lee P, Song T, Stone A, Davies JC. Lung clearance index as an outcome measure in cystic fibrosis clinical trials. Pediatric Pulmonology 2011;46 Suppl 34:282, Abstract no: 201. [CENTRAL: 921614; CFGD Register: BD188d; CRS: 5500125000000389]
67. Donaldson S, Pilewski J, Griese M, Dong Q, Lee PS, for theVX11-661-101SG. VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: interim analysis. Journal of Cystic Fibrosis 2013;12 Suppl 1:S14, Abstract no: WS7.3. [CFGD Register: BD190a; CRS-ID: 5500100000011651]
68. Pilewski JM, Donaldson SH, Cooke J, Lekstrom-Himes J. Phase 2 studies reveal additive effects of VX-661, an investigational CFTR corrector, and ivacaftor, a CFTR potentiator, in patients with CF who carry the F508Del-CFTR mutation. Pediatric Pulmonology 2014;49 Suppl 38:157-9. [CENTRAL: 1015871; CFGD Register: BD190b; CRS: 5500131000000272]
69. Ajayi T, Konstan M, Accurso FJ, De Boeck K, Kerem E, Rowe S, et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis 2013;12 Suppl 1:S64, Abstract no: 63. [CENTRAL: 921666; CFGD Register: BD167h; CRS: 5500100000011670]
70. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respiratory Medicine 2014;2(7):539-47. [DOI: 10.1016/S2213-2600(14)70100-6; PUBMED: 24836205]
71. Kerem E, Wilschanski M, Accurso F, DeBoeck K, Konstan M, Rows S, et al. Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease. Pediatric Pulmonology 2012;47 Suppl 35:312, Abstract no: 252. [CENTRAL: 921643; CFGD Register: BD167e; CRS: 5500125000000035]
72. Kerem E, Wilschanski M, De Boeck K, Sermet-Gaudelus I, Constantine S, Elfring GL, et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis 2011;10 Suppl 1:S17, Abstract no: 65. [CFGD Register: BD167c; MEDLINE: 98135729]
73. Kerem E, Wilschanski M, Melotti P, Sermet-Gaudelus I, DeBoeck K, Rowe SM, et al. Phase 3 study of Ataluren (PTC124®) in nonsense mutation cystic fibrosis (NMCF): demographic & other baseline data. Pediatric Pulmonology 2010;45 Suppl 33:314, Abstract no: 314. [CFGD Register: BD167a; MEDLINE: 98135729]
74. Kerem E, Wilschanski M, Sermet-Gaudelus I, De Boeck K, Accurso FJ, Konstan MW, et al. The effect of Pseusdomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis. Journal of Cystic Fibrosis 2014;13 Suppl 2:S70, Abstract no: 94. [CENTRAL: 996543; CFGD Register: BD167k ; CRS: 5500129000000008]
75. Kerem E, Wilschasnski M, Sermet-Gaudelaus I, de Boeck K, Accurso FJ, Konstan M, et al. Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF). Journal of Cystic Fibrosis 2013;12 Suppl 1:S15, Abstract no: WS7.5. [CENTRAL: 921641; CFGD Register: BD167g; CRS: 5500100000011653]
76. Konstan MW, Accurso FJ, De Boeck K, Kerem E, Rowe SM, Sermet-Gaudelus I, et al. Pretreatment data from phase 3 study of Ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology 2011;46 Suppl 34:295, Abstract no: 232. [CFGD Register: BD167d; MEDLINE: 98135729]
77. Konstan MW, Rowe SM, Accurso FJ, Kerem E, Wilschanski M, De Boeck K, et al. Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis. Pediatric Pulmonology 2013;48 Suppl 36:298, Abstract no: 258. [CENTRAL: 921688; CFGD Register: BD167i; CRS: 5500125000000400]
78. Rowe S, Sermet-Gaudelus I, Konstan M, Kerem E, Wilschanski M, DeBoeck K, et al. Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF). Pediatric Pulmonology 2012;47 Suppl 35:290, Abstract no: 193. [CENTRAL: 921642; CFGD Register: BD167f; CRS: 5500125000000027]
79. Rowe SM, Konstan MW, Accurso FJ, De Boeck K, Sermet-Gaudelus I, Kerem E, et al. The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis. Pediatric Pulmonology 2013;48 Suppl 36:279, Abstract no: 207. [CENTRAL: 921748; CFGD Register: BD167j; CRS: 5500125000000409]
80. Ahrens RC, Standaert TA, Launspach J, Han SH, Teresi ME, Aitken ML, et al. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatric Pulmonology 2002;33(2):142-50. [CFGD Register: BD136d]
81. Aitken ML, Ahrens RC, Karlin DA, Konstan MW, McNamara SC, Regelman WE, et al. Safety of a phase I double-blind placebo-controlled dose escalation trial of oral CPX in adult CF patients. Pediatric Pulmonology 1998;26(S17):276. [CFGD Register: BD136b]
82. McCarty NA, Standaert TA, Teresi M, Tuthill C, Launspach J, Kelley TJ, et al. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatric Pulmonology 2002;33(2):90-8. [CFGD Register: BD136c]
83. McCarty NA, Weatherly MR, Kelley TJ, Konstan MW, Milgram LJH, Teresi M, et al. Multicenter phase I trial of CPX in adults patients with mild CF: results of nasal potential difference measurements. Pediatric Pulmonology 1998;Suppl 17:276. [CFGD Register: BD136a]
84. Pradal U, Casotti V, Delmarco A, Nicolis E, Livraghi A, Conese M, et al. Effects of gentamicin on ion transport, MRNA and protein CFTR expression in patients with R1162X: A double blind placebo controlled study. Pediatric Pulmonology 2002;34 Suppl 24:263. [CFGD Register: BD145]
85. Romano L, Casciaro R, Vanini P, Zegarra-Moran O, Negro I, Minuto N, et al. Reduction of sweat ion concentrations following topical application of gentamicin in CF patients carrying nonsense mutations. Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P11. [CFGD Register: BD144b]
86. Romano L, Sacchi R, Zegarra-Moran O, Vanini P, Guerriero F, Casciaro R, et al. Effects of topical applications of gentamicin on sweat test in CF patients carrying nonsense-mutations. Pediatric Pulmonology 2000;30 Suppl 20:250. [CFGD Register: BD144a]
87. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. American Journal of Respiratory and Critical Care Medicine 1998;157(2):484-90. [CFGD Register: BD146b; MEDLINE: 98135729]
88. Rubenstein RC, Zeitlin PL. A randomized, double blind, placebo-controlled trial of sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function. Pediatric Pulmonology 1997;24 Suppl 14:272. [CFGD Register: BD146a]
89. Rubenstein RC, Propert KJ, Reenstra WW, Skotleski ML. A pilot trial of the combination of phenylbutyrate and genistein. Pediatric Pulmonology 2006;41 Suppl 29:294. [CFGD Register: BD149]
90. Sermet-Gaudelus I, De Boeck K, Casimir GJ, Vermeulen F, Leal T, Mogenet A, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. American Journal of Respiratory & Critical Care Medicine 2010;182(10):1262-72. [CFGD Register: BD167b; MEDLINE: 98135729]
91. Wilschanski M, Virgilis D, Strauss-Liviatan N, Tal A, Bentur L, Blau H, et al. Gentamicin causes functional expression of CFTR in CF patients carrying stop mutations: a double-blind placebo controlled trial. Pediatric Pulmonology 2000;30 Suppl 20:244. [CFGD Register: BD143a; MEDLINE: 98135729]
92. Wilschanski M, Yahav J, Blau H, Bentur L, Rivlin J, Aviram M, et al. Restoration of CFTR function by gentamicin in cystic fibrosis patients carrying stop mutations: a double blind placebo controlled trial. Gastroenterology 2003;124(4 Suppl 1):A582. [CFGD Register: BD143c]
93. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New England Journal of Medicine 2003;349(15):1433-41. [CFGD Register: BD143b]
94. Kerem E, Yaakov Y, Armoni S, Pugatsch T, Shoseyov D, Cohen M, et al. PTC124 induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis. Pediatric Pulmonology 2008;43 Suppl 31:294. [CFGD Register: BD22d; MEDLINE: 98135729]
95. Sermet-Gaudelus I, De Boeck K, Casimir G, Leal T, Vermeulen F, Mogenet A, et al. Children with nonsense-mutation-mediated cystic fibrosis respond to investigational treatment with PTC124. Pediatric Pulmonology 2008;43 Suppl 31:313. [CFGD Register: BD22c; MEDLINE: 98135729]
96. Sermet-Gaudelus I, Leal T, De Boeck K, Casimir G, Hanssens L, Hage P, et al. PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF. Journal of Cystic Fibrosis 2008;7 Suppl 2:S22. [CFGD Register: BD22a; MEDLINE: 98135729]
97. Wilschanski M, Armoni S, Yaakov Y, Blau H, Shoseyov D, Cohen M, et al. PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense -mutation-mediated CF. Journal of Cystic Fibrosis 2008;7 Suppl 2:S22. [CFGD Register: BD22b; MEDLINE: 98135729]
98. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Molecular Therapy 2002;6(1):119-26. [CFGD Register: BD148]
99. De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Chan J, et al. The effect of ivacaftor, a CFTR potentiator, in patients with cystic fibrosis and a non-G551D-CFTR gating mutation, the KONNECTION study. Journal of Cystic Fibrosis 2014;13 Suppl 2:S1, Abstract no: WS1.1. [CENTRAL: 998097; CFGD Register: BD201b; CRS: 5500125000000707]
100. De Boeck K, Paskavitz J, Chen X, Higgins M. Ivacaftor, a CFTR potentiator, in cystic fibrosis patients who have a non-G551D-CFTR gating mutation: phase 3, part 1 results. Pediatric Pulmonology 2013;48 Suppl 36:292, Abstract no: 241. [CENTRAL: 962356; CFGD Register: BD201a; CRS: 5500125000000421]
101. Moss R. Study of ivacaftor in subjects with cystic fibrosis who have the R117H-CFTR mutation (KONDUCT). Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014) 2014. [CENTRAL: 1012721; CFGD Register: BD204b; CRS: 5500131000000199;: NCT01614457]
102. Moss R, Flume PA, Elborn J, Cooke J, Rowe SM, McColley SA, et al. Effects of ivacaftor in CF patients with R117H-CFTR. Pediatric Pulmonology 2014;49 Suppl 38:221, Abstract no: 17. [CENTRAL: 1012722; CFGD Register: BD204c; CRS: 5500131000000201]
103. Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, et al. Ivacaftor treatment in patients with cystic fibrosis who have an R117H-CFTR mutation, the KONDUCT study. Journal of Cystic Fibrosis 2014;13 Suppl 2:S44, Abstract no: WS23.6. [CENTRAL: 996577; CFGD Register: BD204a; CRS: 5500129000000012]
104. Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function. Ongoing study September 2012.
105. Short-Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients. Ongoing study October 2013.
106. Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends in Pharmacological Sciences 2007;28(7):334-41.
107. Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Human Mutation 2002;19(6):575-606.
108. Hospital for Sick Children in Toronto. Cystic Fibrosis Mutation Database. www.genet.sickkids.on.ca/StatisticsPage.html (accessed 01 March 2012).
109. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
110. Hamosh A, FitzSimmons SC, Macek Jr M, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. Journal of Pediatrics 1998;132(2):255-9.
111. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
112. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
113. Higgins JPT, Deeks JJ, Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
114. McKone EF, Aitken ML. Cystic fibrosis: disease mechanisms and therapeutic targets. Drug Discovery Today: Disease Mechanisms 2004;1(1):137-43.
115. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
116. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245(4922):1066.
117. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Annals of Human Genetics 2003;67(5):471-85.
118. Sinha IP, Southern KW, Dwan K, Patel S. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD010966]
119. Southern KW. Delta F508 in cystic fibrosis: Willing but not able. Archives of Disease in Childhood 1997;76(3):278-82.
120. Southern KW. Cystic fibrosis and formes frustes of CFTR-related disease. Respiration: International Review of Thoracic Diseases 2007;74(3):241-51.
121. UK CF Trust. Cystic fibrosis: our focus. www.cysticfibrosis.org.uk/media/598466/annual-data-report-2013-jul14.pdf (accessed 07 Jan 2015).
122. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proceedings of the National Academy of Sciences of the United States of America 2009;106(44):18825-30. [DOI: 10.1073/pnas.0904709106]
123. Whiting P, Al M, Burgers L, Westwood M, Ryder S, Hoogendoorn M, Armstrong N, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technology Assessment (Winchester, England) 2014;18(18):1-106. [DOI: 10.3310/hta18180]